news
Mylan rejects Teva’s $40.1 billion cash and stock offer
28 April 2015 | By Victoria White
Mylan has announced that its Board of Directors has unanimously rejected the unsolicited expression of interest from Teva to acquire the Company...
List view / Grid view
Teva Pharmaceutical Industries Ltd
news
First patient enrolled in Phase II study evaluating laquinimod for primary progressive MS
24 April 2015 | By Victoria White
The first patient has been enrolled in a Phase II study evaluating laquinimod, an investigational, oral, immune modulator, for the treatment of PPMS...
news
Teva makes $40 billion offer for Mylan
22 April 2015 | By Victoria White
Teva has announced their proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share...
news
Teva announces launch of generic Baraclude® Tablets, 0.5mg and 1mg, in the United States
5 September 2014 | By Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the United States...
news
Teva announces UK High Court gives positive judgment in the company’s patent case against AstraZeneca
3 September 2014 | By Teva
Court decision invalidating AZ's patent supports Teva’s launch of DuoResp Spiromax® in UK...
news
Teva comments on receipt of first paragraph IV notice for COPAXONE® 40 mg/mL (glatiramer acetate injection) formulation
8 August 2014 | By Teva
Teva Pharmaceutical Industries Ltd. confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE® 40 mg/mL...
news
Teva completes acquisition of Labrys
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
news
Leading U.S. proxy advisory firm supports Teva nominees and other shareholders’ meeting proposals
17 July 2014 | By Teva
Teva Pharmaceutical Industries Ltd. reported that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director...
news
Teva announces FDA acceptance of NDA filing for investigational short-acting beta-agonist inhaler (Albuterol MDPI)
14 July 2014 | By Teva
First breath-actuated dry-powder SABA inhaler to be accepted by FDA for review...
news
Teva receives CHMP positive opinion for Seasonique® extended-regimen contraceptive for marketing authorization in several European countries
4 July 2014 | By Teva
An extended regimen oral contraceptive that provides quarterly menses – a new concept for women in Europe...
news
Teva reaches settlements in NUVIGIL® patent case
18 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablet...
news
FDA approves expanded label for AZILECT® for treatment across all stages of Parkinson’s Disease
9 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration has expanded the indication for AZILECT® (rasagiline tablets)...
news
Teva to acquire Labrys Biologics, Inc.: Novel migraine prophylaxis treatment adds significant new dimension to Teva’s growing pain care franchise
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...
news
Teva announces favorable European Patent Office ruling in COPAXONE® patent proceeding
28 May 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party...
news
FDA approves Teva’s SYNRIBO® (omacetaxine mepesuccinate) for injection for home administration
6 May 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has approved SYNRIBO® (omacetaxine mepesuccinate) for injection...
